![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
![Publish Open Access Finland]({"type":"image" , "src" : "/sda/110396/JournalAd-OA-Agreements.gif"})
![Dialogues in Clinical Neuroscience is now a fully Open Access journal]({"type":"image" , "src" : "/sda/111031/JournalAd-Announce-Neuroscience.jpg"})
ABSTRACT
Optic perineuritis can be a manifestation of infectious and systemic inflammatory disorders, but the majority of cases are idiopathic. Myelin oligodendrocyte glycoprotein (MOG)-IgG-positive optic neuritis has been reported to be associated with optic nerve sheath enhancement. This report describes two MOG-IgG patients with clinical, radiological and therapeutic response consistent with optic perineuritis. MOG-IgG may account for many cases of previously described idiopathic optic perineuritis. Vision loss with optic nerve sheath enhancement on MRI should prompt testing for MOG-IgG.
Acknowledgements
The authors thank John Schmeling for technical support, Mary Curtis for secretarial assistance, and Jessica Sagan for study coordination.
Author contributions
Dr Lopez Chiriboga, Dr Van Stavern, and Dr Chen were involved in drafting and revising the manuscript for content, including medical writing for content, study concept and design, analysis and interpretation of data, acquisition of data and study supervision.
Revising the manuscript for content and analysis and interpretation of data: all authors.
Declaration of interest
S. Lopez, J. Fryer, G. Van Stavern and J.Chen have no disclosures.
E. P. Flanagan receives research support from Medimmune but has not received personal compensation.
M. T. Bhatti is a consultant for Celgene.
S.J. Pittock holds patents that relate to functional AQP4/NMO-IgG assays and NMO-IgG as a cancer marker; has a patent pending for GFAP as markers of neurological autoimmunity and paraneoplastic disorders; consulted for Alexion and Medimmune; and received research support from Grifols, Medimmune, and Alexion. All compensation for consulting activities is paid directly to Mayo Clinic.